Related Experiment Video
Updated: Nov 18, 2025
Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
Published on: November 2, 2014
A Retrospective Observational Study of Anlotinib in Patients with Platinum-Resistant or Platinum-Refractory
Qingli Cui1, Yanhui Hu1, Dongyang Ma1
1Department of Integrated Traditional and Western Medicine, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou City, Henan Province, People's Republic of China.
Objective:
Anlotinib, an oral small-molecular tyrosine kinase inhibitor (TKI) on tumor angiogenesis and growth, has a wide spectrum of inhibitory effects on targets such as vascular endothelial growth factor receptors 2/3 (VEGFR2/3), etc. The efficacy and safety of anlotinib in the treatment of platinum-resistant or platinum-refractory ovarian cancer were evaluated.
Patients And Methods:
Patients with platinum-resistant or platinum-refractory ovarian cancer that treated with anlotinib in the Affiliated Cancer Hospital of Zhengzhou University from May 2018 to March 2020 were included. Medical records were reviewed in terms of objective response, survival outcomes, and safety.
Results:
A total of 38 patients were analyzed. The median progression-free survival and the median overall survival were 7.7 months (95% CI: 6.7-8.7) and 16.5 months (95% CI: 13.3-19.7), respectively. About 17 patients received anlotinib monotherapy, and the median progression-free survival was 7.7 months (95% CI: 6.3-9.1). A total of 19 cases received anlotinib plus chemotherapy with a median progression-free survival of 8.0 months (95% CI: 4.8-11.2). A total of 2 cases received anlotinib plus anti-PD-1 antibody pembrolizumab, and 1 case had partial response, the other progressive disease. The objective response rate was 42.1% while the disease control rate was 86.8%. A total of 5 patients experienced dose reduction from 12 mg to 10 mg because of adverse effects. The most common adverse effects were hypertension (31.6%), fatigue (28.9%), anorexia (26.3%) and hand-foot syndrome (23.7%). No treatment-related deaths were recorded.
Conclusion:
Anlotinib produced moderate improvements in progression-free survival and overall survival in patients with platinum-resistant or platinum-refractory ovarian cancer. It indicates that anlotinib maybe a new treatment option for patients with platinum-resistant or platinum-refractory ovarian cancer.
Insights
Anlotinib, an oral tyrosine kinase inhibitor, showed moderate improvements in progression-free and overall survival for patients with platinum-resistant ovarian cancer. This suggests anlotinib may be a viable new treatment option for this patient group.
Area of Science:
- Oncology
- Pharmacology
- Clinical Trials
Background:
- Anlotinib is an oral small-molecule tyrosine kinase inhibitor (TKI) targeting tumor angiogenesis and growth, with inhibitory effects on VEGFR2/3.
- Platinum-resistant or platinum-refractory ovarian cancer presents a significant challenge in treatment, necessitating novel therapeutic strategies.
Purpose of the Study:
- To evaluate the efficacy and safety of anlotinib in patients with platinum-resistant or platinum-refractory ovarian cancer.
- To assess anlotinib's impact on objective response, survival outcomes, and adverse events in this patient population.
Main Methods:
- A retrospective review of medical records for 38 patients treated with anlotinib at the Affiliated Cancer Hospital of Zhengzhou University (May 2018 - March 2020).
- Analysis included objective response, progression-free survival (PFS), overall survival (OS), and safety profiles.
- Patients received anlotinib as monotherapy, or in combination with chemotherapy or pembrolizumab.
Main Results:
- The median PFS was 7.7 months and the median OS was 16.5 months.
- Anlotinib monotherapy yielded a median PFS of 7.7 months; combination with chemotherapy resulted in a median PFS of 8.0 months.
- The objective response rate was 42.1%, and the disease control rate was 86.8%. Common adverse effects included hypertension, fatigue, anorexia, and hand-foot syndrome. No treatment-related deaths occurred.
Conclusions:
- Anlotinib demonstrated moderate improvements in PFS and OS for patients with platinum-resistant or platinum-refractory ovarian cancer.
- Anlotinib represents a potential new treatment option for this challenging patient group.
- Further investigation into anlotinib's role in ovarian cancer treatment is warranted.
More Related Videos
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
